Ying Xue

Ms. Ying Xue


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
CJChen Jiang
Chen Jiang
JQJunnan Qi
Junnan Qi
HZHongyi Zou
Hongyi Zou
OLOscar Lopez
Oscar Lopez
XXXiang-Qun Xie
Xiang-Qun Xie
YXYing Xue
Ying Xue
Background: Several hypotheses suggest that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD), and antidiabetic medications may influence cognitive function in these patients. Objective: This study aims to provide a comprehensive evaluation of the impact of single and combination antidiabetic therapies on cognitive function in patients with both AD and T2DM. Methods: We analyzed data from the National Alzheimer's Coordinating Center (NACC), covering a 17-year period from June 2005 to August 2022. This study included 3234 patients with both AD and T2DM. After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model. Patients were categorized based on their longitudinal use of oral antidiabetic medications. Results: Based on the 964 patients’ cohort, the study found that patients receiving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with a dipeptidyl peptidase 4 inhibitor (DPP-4i) (RR = 1.132 [1.021, 1.256], p = 0.019) experienced a significantly slower decline in MMSE scores over time when compared to patients receiving metformin with thiazolidinediones (TZD). Conclusions: This study demonstrates that combination therapies involving metformin with sulfonylureas or DPP-4i are associated with a slower rate of cognitive decline compared to metformin with TZD in patients with AD and T2DM. These findings provide novel evidence for the long-term cognitive benefits of specific antidiabetic therapies and offer valuable insights for clinical decision-making in this dual-affected population.